Severe disease activity in MS patients treated with cladribine after fingolimod withdrawal

[1]  J. Flores-Rivera,et al.  Severe fingolimod rebound syndrome after switching to cladribine treatment. , 2020, Multiple sclerosis and related disorders.

[2]  S. Schmidt,et al.  Severe rebound after cessation of fingolimod treated with ocrelizumab with coincidental transient aggravation: report of two cases , 2019, Therapeutic advances in neurological disorders.

[3]  M. Sormani,et al.  Different MRI patterns in MS worsening after stopping fingolimod , 2019, Neurology: Neuroimmunology & Neuroinflammation.

[4]  S. Gil-Perotín,et al.  Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing–remitting multiple sclerosis is effective and safe , 2019, Journal of Neurology.

[5]  R. Grasso,et al.  Clinical activity after fingolimod cessation: disease reactivation or rebound? , 2018, European journal of neurology.

[6]  A. Bar-Or,et al.  Reconstitution of the peripheral immune repertoire following withdrawal of fingolimod , 2017, Multiple sclerosis.

[7]  K. Schmierer,et al.  Both cladribine and alemtuzumab may effect MS via B-cell depletion , 2017, Neurology: Neuroimmunology & Neuroinflammation.

[8]  K. Schmierer,et al.  Cladribine to treat disease exacerbation after fingolimod discontinuation in progressive multiple sclerosis , 2017, Annals of clinical and translational neurology.

[9]  E. Waubant,et al.  Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment. , 2016, JAMA neurology.

[10]  P. Vermersch,et al.  MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study , 2013, Journal of Neurology.